MEDIPOST announced on July 4 that it has acquired a Japanese patent for hair loss prevention stem cell composition.

This patent is entitled the ‘Hair growth-promoting function of small-sized stem cells and the use thereof’, in which the present invention relates to a composition for preventing hair loss and promoting hair growth using a stem cell in a relatively small size or a culture thereof.

MEDIPOST explained that “the technology has proven to show that small mesenchymal stem cells separated from the cord blood or their culture medium is excellent in preventing hair loss and promoting hair growth.”

MEDIPOST has been researching this technology with the support of the government as the host of the ‘Global Advanced Biomedical Technology Development Project’ jointly promoted by the Ministry of Science, ICT and the Ministry of Health and Welfare.

MEDIPOST plans to use the patent as a basis for research on hair loss treatment using the SMUP-Cell, which is the next-generation high-efficiency stem cell therapy.

Meanwhile, MEDIPOST holds 76 patents in the fields of cord blood and disease treatment technology using cord blood stem cells.